Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BRM421 in Dry Eye Disease
NCT05695781Phase 3Completed
- Sponsor
- BRIM Biotechnology, Inc.
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing BRM421 with Vehicle (2 arms). Primary endpoints: Change From Baseline in Total Corneal Fluorescein Staining Score and Change From Baseline in Visual Analog Scale (VAS). Started Feb 2023; status: completed.
02
Drugs
BRM421
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05695781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695781.